INTERNATIONAL JOURNAL OF
PURE AND APPLIED SCIENCE & TECHNOLOGY

SIMULTANEOUS ESTIMATION OF HYDROCHLORTHIAZIDE AND CANDESARTAN CILEXTIL IN BULK AND PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC PDA METHOD

Ms. Nayela Ghazal[1], Dr. Kona Shravan Kumar[2], Mrs.Anitha Surakala[3]

ABSTRACT: For hypertension, a combination of hydrochlorothiazide and candesartan cilextil is used. This study set out to create and test an RP-HPLC technique for the simultaneous quantification of hydrochlorothiazide and candesartan cilextilin in both bulk and dose forms that was easy to use, cost-effective, and efficient. At a flow rate of 1.2 mL/min, eluents were monitored at 262nm while chromatographic analysis was carried out on a Phenomenex C18RP column (250 x 4.6mm; 5μm) with a mobile phase consisting of 10mM ammonium acetate: acetonitrile (65:35% v/v). Both Hydrochlorothiazide and Candesartan cilextil exhibited good linearity in the concentration range of 7.8-18.8μg/mL and 10-26μg/mL, respectively, with retention times of 3.6 and 6.8 minutes, and a regression coefficient (R^2) of 0.996 and 0.998, respectively. The following validation metrics were assessed: specificity, linearity, accuracy, robustness, stability, limit of detection, and limit of quantification. All instances passed regulatory standards for validation parameters. The percentages of recoveries varied from 98 to 102 (with an RSD less than 2). Accurate bulk and pharmaceutical dosage form simultaneous estimation of hydrochlorothiazide and candesartan cilextilin was achieved using the established RP-HPLC technique.

Keywords: Candesartan cilextil, Hydrochlorothiazide, Phenomenex C18RP column, Method Validation, Photo diode array (PDA detection)

INTRODUCTION:

A non-peptide tetrazole derivative, CST is 2-ethoxy-3 [21- (1H- tetrazol-5-yl) biphenyl-4yl methyl] and is active when taken orally. the carboxylic acid of -3H-benzimiadazole 1-ethyl ester of cyclohexyloxycarbonyl functions. In several tissues, including adrenal glands and vascular smooth muscle, CST specifically inhibits the binding of angiotensin II to AT1. 6-chloro-3,4-dihydro-2H-1,2,4-benzo thiadiazine-7-sulfonamide 1,1-dioxide1-3 is the molecular formula for HCTZ. It is thought that HCTZ reduces peripheral vascular resistance, which is why it is often used to treat hypertension 2, 3. As the first-line therapy for hypertension 1-3, fixed-dose combinations of anti-hypertensive medications may simplify dosage regimens, increase compliance, enhance hypertension management, minimize dose-dependent adverse effects, and save cost.

Associate professor[1,2], Assistant professor[3]
Department of Pharmaceutical Chemistry
Global College of Pharmacy, Hyderabad. Chilkur (V), Moinabad (M), Telangana- 501504.

FIG. 1: CANDESARTAN CILEXITIL

FIG. 2: HYDROCHLOROTHIAZIDE

Literature review reports for the quantitative determination of HCTZ and CST in combination with other drugs like Losartan [4], Amlodipine besylate [5, 17],Lisinopril [6], Irbesartan [7], Valsartan [8], Olmesartan [9, 17], Telmisartan [10] by HPLC, stability indicating method [11] Spectrophotometry [12] and Fluorimetry [13] were reported. Literature survey reveals that there were only few validated RP-HPLC-PDA methods reported for the simultaneous estimation of HCTZ and CST in bulk and tablet dosage forms [14 - 16]. However, the reported HPLC methods for the estimation of HCTZ and CST in combination with other anti-hypertensive and diuretics used non-volatile buffers like phosphate buffers in mobile phase which are not LC-MS compatible. Hence, the present investigation was aimed at developing a validated RP-HPLC-PDA method for the simultaneous estimation of HCTZ and CST in bulk and dosage forms.

MATERIAL AND METHODS: CST and HCTZ
were procured as a gift samples from Hetero drugs Ltd, India. Ammonium acetate, water and methanol were purchased from E. Merck, Mumbai, India. All the solvents and reagents used were of HPLC grade. Tablet formulation contains HCTZ (25mg) and CST (32mg) was punched by direct compression technique, due to the unavailability of tablet formulation in Indian market.

Equipment: A Shimadzu Prominence HPLC system provided with DGU-20A3 degasser, LC-20AD binary pumps, SIL-20AHT auto sampler, and SPD- M20A PDA detector was used. Data acquisitionwas carried out using LC solutions software. The chromatographic analysis was performed using Phenomenex C18 RP column (250×4.6mm; 5μm) as a stationary phase.

Chromatographic Conditions: Mobile phase was pumped at a flow rate of 1.2mL/min using a binary mixture of 10mM ammonium acetate: acetonitrile (65:35% v/v) in isocratic mode. The mobile phase was filtered through nylon disc filter of 0.45μm(Millipore) and sonicated for 3 min before use for degassing. The injection volume of 10μL was given and the detection wavelength for HCTZ and CST was set at 262nm and the separation was achieved at ambient temperature.

Preparation of Stock and Standard Solutions: The stock solutions of concentration

1000ppm were prepared for HCTZ and CST by dissolving 10mg of the reference standards separately using methanol as diluents in 10ml volumetric flasks. Further sub stocks were prepared by consuming the appropriate volume of the stock solution and diluted with ammonium acetate to get the required concentrations of the working standard solutions at a concentration range of 7.8-18.8µg/mL HCTZ and 10-26µg/mL of CST.

Validation of the HPLC Method: The proposed method was validated as per ICH guidelines.

Linearity: Calibration graphs were constructed across the range of the analytical procedure with a minimum of five concentrations. A series of standard dilutions of HCTZ and CST were prepared over a concentration range of 7.8- 13.8µg/mL (7.8, 10.8, 13.8, 15.8, 18.8 µg/mL) and

10-26 µg/mL (10, 14, 18, 22, 26 µg/mL)

respectively from stock solution and injected in triplicate (n = 3). Linearity was evaluated by a plot of peak areas as a function of analyte concentration, and the test results were evaluated by appropriate statistical methods where by slope, intercept, and regression (R^2) and correlation coefficients (R) were calculated and the data was given in **Table 1**.

Precision: Precision is the measure of closeness of the data values to each other for a number of measurements under the same analytical conditions. Repeatability was assessed by using a minimum of six determinations at 100% of the test concentration. The standard deviation and the relative standard deviation were reported for precision. Less than 2% RSD for peak areas indicates the precision of the developed method.

Specificity: Specificity is a measure of the degree of interference in the analysis of the complex sample mixtures such as analyte mixed with the formulation excipients or the known impurities. Specificity of the method was carried out by comparing chromatogram of the placebo with that of the sample for checking any interference peaks. Absence of interference peaks

of excipients in the tablet indicates the specificity of the proposed method.

Accuracy: Accuracy was established across the specified range of the analytical procedure. Accuracy of the method was tested by spiking 80, 100, and 120% of standards to 7.8µg/mL of HCTZ and 10µg/mL of CST test solution. These solutions were analyzed by developed method in triplicate. The % recovery and % RSD were calculated at each level of addition.

Limit of Detection (LOD) and Limit of Quantification (LOQ): LOD and LOQ were calculated based on calibration curves and were expressed as LOD = $(3.3 \times \sigma)/m$; LOQ= $(10.0 \times \sigma)/m$ (Where, σ is the standard deviation of the y- intercepts of the three regression lines and m is mean of the slopes of the three calibration curves).

Robustness: To determine the robustness of the method developed, the experimental conditions were deliberately altered and the chromatographic parameters *viz.*, capacity factor, tailing factor, theoretical plate number and % assay were recorded. The flow rate of the mobile phase was 1.2mL/min. To study the effect of flow rate, the flow rate was changed by 20%. The effect of wavelength was studied by changing wavelength by ±1nm and the effect of mobile phase was studied by changing the mobile phase by ±2% v/v of organic phase.

System Suitability: System suitability was carried out by injecting a standard concentration by increasing the injection volumes in the range of 10-50μL. The system suitability test parameters were noted and % RSD was calculated.

Assay: Twenty tablets were weighed and finely powdered and the powder equivalent to 10mg was accurately weighed and transferred into a 10mL volumetric flask. Dissolve in 5mL methanol and vortexed for 5min and made up to the mark with methanol, centrifuged and filtered using Nylon disposable syringe filter (13mm, 0.45μm). An aliquot of filtrate was diluted with ammonium acetate and analyzed in triplicate. The amount present in the each tablet was quantified by comparing the area of HCTZ and CST standards with that of the sample.

Preparation of HCTZ and CST Tablets by Direct Compression Technique: Due to the unavailability of marketed tablet formulation for HCTZ and CST combination in Indian market, tablets were prepared in house by direct compression method using carboxy methyl cellulose calcium, hydroxyl propyl cellulose, lactose monohydrate, corn starch and polyethylene glycol 8000 as excipients. All the ingredients were passed through sieve # 80 before mixing. Initially drugs and filler were mixed thoroughly, followed by the addition of required amount of colloidal silicon dioxide and mixed thoroughly for 5min in a poly bag. Required amounts of SSG was added and mixed thoroughly for 5 min. Finally, the resultant powder blend (for 20 tablets) of the required formulation was compressed on single punch tablet press (Cadmach, India) using 10mm punches (round shape) maintaining a hardness range of compressed tablets between 4 - 5 kg/cm^2.

RESULTS AND DISCUSSION: Various HPLC,
UV methods were published for the estimation of HCTZ and CST in combination with other drugs like Losartan, Amlodipine besylate, Lisinopril, Irbesartan, telmisartan and olemesartan but only few methods were reported on the simultaneous quantification of HCTZ and CST in bulk and dosage forms using phosphate buffers. Hence, the present investigation was aimed to develop a simple, economical RP-HPLC-PDA method for the determination of HCTZ and CST in bulk and dosage forms.

Method Development: Mobile phase optimization was initially carried with Phenomenex C18RP column (250 x 4.6 mm) using 10mM ammonium acetate and methanol as mobile phase at different ratios at 1mL/min flow rate, the HCTZ and CST were eluted at 3.17 and 14.90 min respectively but asymmetrical peaks were seen. In the final trail, mobile phase ratio was changed to 10mM ammonium acetate and acetonitrile (65:35%v/v) using Phenomenex C18RP column at a flow rate of 1.2mL/min and peaks were monitored at 262nm. Under these conditions, HCTZ and CST peaks were eluted with in desired run time and the peak symmetry was satisfactory. The retention times were 3.65 min and 6.49 min respectively for HCTZ and CST. For quantitative analytical purpose wavelength was set at 262 nm, which provided better reproducibility with no interference. The method was validated as per ICH guidelines. The peak purity index was found to be greater than 0.9999 and peak purity profiles were shown in **Fig. 7** along with UV spectra.

Method Validation: The method has been validated as per ICH - Guidelines for following parameters.

Linearity: The range for the reliable quantification was set at the concentrations of 7.8-18.8μg/mL and 10-26μg/mL of HCTZ and CST respectively. This range was selected based on 80-120% of the standard concentration used for accuracy and were analyzed in triplicate. Peak areas and concentrations were subjected to least square regression analysis to calculate regression equation. The regression coefficient (R^2) was found to be 0.996 and 0.998 indicating a linear response over the range used. The data from the calibration curve was given in **Table 1** and shown in **Fig. 3**.

CALIBRATION CURVE OF HCTZ | CALIBRATION CURVE OF CST

FIG. 3: CALIBRATION CURVE OF HCTZ AND CST

Precision: Precision was carried out in terms of repeatability. Repeatability of standard application was assessed by using six replicates at a concentration of 10.8 µg/mL of HCTZ and 14 µg/mL of CST. The data was given in **Table 1**shown in **Fig. 4**. The % RSD was found to be NMT2, indicating the repeatability of the method.


FIG. 4: OVERLAY OF SYSTEM PRECISION CHROMATOGRAMS OF STANDARD MIXTURES (7.8µg/ml OF HCTZ AND 10µg/ml OF CST) WITHOUT BASE SHIFT

Specificity: The specificity of the method was established by injecting the solutions of diluent, placebo, standard, test sample (formulation) individually to examine for any interference, from the overlay of chromatograms as shown in **Fig. 5** and **6** and the 3D plots of placebo and test samples it can be inferred that there were no co-eluting

peaks at the retention time of HCTZ and CST, this shows that peak of analyte was pure and the excipients in the formulation did not interfere with the analysis and the peak purity indices for sample and standard was found to be greater than 0.999 and this confirms specificity of the method.


FIG. 5: CHROMATOGRAM OF HCTZ (7.8µg/ml) AND CST (10µg/ml) MIXTURE (A); PEAK PURITY CURVES OF HCTZ AND CST (B) AND (C) - UV SPECTRA

Accuracy: Accuracy of the proposed method was ascertained by performing recovery studies using external standard addition method by spiking the known quantities of standard at 80%, 100% and 120% to the test solution of 10ug/mL. These solutions were analyzed in triplicate in each level of addition. The % RSD and the % recovery were within the acceptable limit in all cases. It is evident from the results of accuracy study given in **Table 1**,that the proposed method enables very accurate quantitative estimation of HCTZ and CST.

FIG. 6: OVERLAY OF THE DILUENT (A) PLACEBO (B) STANDARD (C) AND SAMPLE (D) CHROMATOGRAMS

Assay: Assay of tablets containing 25mg of HCTZ and 32mg of CST was performed by the proposed method and the % assay of the formulation was calculated as an average of 3 determinations, which was about 100.29 ± 0.45 and 100.52 ± 0.44 for HCTZ and CST respectively. These results indicate that the present HPLC method can be successfully used for the assay of HCTZ and CST in bulk and combination dosage forms.

TABLE 1: LINEARITY, PRECISION, ACCURACY AND ASSAY DATA OF HCTZ AND CST

	Validation data of HCTZ and CST		
	Parameters	**HCTZ**	**CST**
	Range	7.8-18.8µg/mL	10-26µg/mL
	Regression equation	Y=22826x-51498	Y=21669x-90599
Linearity (n = 3)	Regression coefficient (R^2)	0.996	0.998
	Correlation coefficient (r)	0.998	0.999
Accuracy (n = 3)	% Level of Addition	Mean % Recovery (RSD)	Mean % Recovery (RSD)
	80	94.55(0.45)	100.59 (0.15)
	100	101.40(0.33)	100.67 (0.51)
	120	103.86(1.08)	100.86 (1.78)
Precision (n = 6)		HCTZ	CST
System Precision	Average Peak area of the standard sample (RSD)	147786 (0.82)	131045 (0.66)
Method Precision	Average peak area of the Assay sample (RSD)	112120(0.63)	143443 (1.06)
Assay in mg (n = 3)	Mean ± SD	25.08 (0.41)	32.26 (0.99)

Limit of Detection (LOD) and Limit of Quantification (LOQ): LOD and LOQ were determined based on statistical calculation from the calibration curves, where LOD = $(3.3 \times \sigma)/m$; LOQ= $(10.0 \times \sigma)/m$ (σ is the standard deviation of the y-intercepts of the three regression lines and m is mean of the slopes of the three calibration curves). The limit of detection for HCTZ and CST was found to be 0.803µg/mL and 2.435µg/mL respectively; the drug peak can be detected without any base line noise at this concentration. The limit of quantification for HCTZ and CST was found to be 0.377µg/mL and 1.143µg/mL respectively.

Robustness: As part of the robustness, deliberate changes in the flow rate, mobile phase and wavelength were made to evaluate the impact on the method. Retention times were significantly changed with flow rate, mobile phase and there was no alteration of the retention time was observed with the change in wavelength. % assay

was also estimated under these changed conditions and the results were given in **Table 2**. The symmetry parameters like capacity factor, theoretical plate number and assay were significant and were within the limits. These results indicate the method is robust in terms of change in flow rate, mobile phase and wavelength.

System Suitability: System suitability testing is an integral part of the analytical procedure. System suitability studies were carried out by injecting the standard concentration of 7.8µg/mL and 10µg/mL for HCTZ and CST respectively at injection volumes ranging from 10µL to 50µL respectively.

The RSD values for system suitability test parameters like retention time [R_t = 3.7 (0.5)], tailing factor [T_f = 1.4 (1.5) of HCTZ], [R_t = 6.56 (0.17)], tailing factor [T_f =1.33 (1.18) of CST] and

TABLE 2: ROBUSTNESS DATA OF HCTZ AND CST

theoretical plate number [8603 (0.43) for HCTZ and 5755 (0.34) for CST] were less than 2% indicating the present conditions were suitable for the analysis of HCTZ and CST in tablets.

Drug	Composition	Retention time (min)	Theoretical plates (N)	Tailing factor	% Assay
% Mobile phase composition					
HCTZ	63:37	3.50	8136	1.42	98.7
	65:35	3.64	8191	1.45	99.7
	67:33	3.85	8463	1.42	98.5
CST	63:37	5.26	6926	1.33	101.1
	65:35	6.68	6119	1.27	101.9
	67:33	8.90	5355	1.16	101.5
Wavelength (nm)					
HCTZ	260	3.64	8191	1.45	99.4
	262	3.64	8183	1.45	99.7
	264	3.64	8190	1.45	99.8
CST	260	6.68	6119	1.27	101.6
	262	6.68	6119	1.27	101.9
	264	6.68	6123	1.27	101.7
Flow rate (mL/min)					
HCTZ	1.1	3.98	8346	1.45	99.4
	1.2	3.64	8191	1.45	99.7
	1.3	3.38	7252	1.43	100.4
CST	1.1	7.17	5961	1.27	100.6
	1.2	6.68	6119	1.27	101.9
	1.3	6.23	6110	1.26	101.4

Stability of the Stock Solution: The stability of the stock solution was determined by analyzing the samples under refrigeration (8 ± 1 °C) at different time intervals up to 48hrs. The % variation in assay values at different time intervals were found to be less than 2 of the initial zero time interval solution, thus

indicating that the solutions were stable for a period of 48hrs when stored at 8 ± 1 °C and the results were given under **Table 3**.

TABLE 3: STABILITY DATA FOR HCTZ AND CST

Time interval	% Variation in peak area	
	HCTZ	**CST**
0 days	0	0
48 hrs	0.880	1.030

CONCLUSION:

The proposed method has the advantage of simplicity and convenience for the simultaneous estimation of HCTZ and CST by RP- HPLC-PDA method in bulk and pharmaceutical dosage forms. The method was validated as per International Conference on Harmonisation (ICH) Guidelines, and found to be applicable for routine quality control analysis for the simultaneous estimation of HCTZ and CST in using isocratic mode of elution. The results of linearity, precision, accuracy and specificity, proved to be within the limits. The method provides selective quantification of HCTZ and CST without interference from diluents and placebo. Therefore, this method can be employed in quality control to estimate the amount of HCTZ and CST in bulk and pharmaceutical dosage forms.

REFERENCES:

First edition, 2001, United States Pharmacopoeia XXIV NF 19.

2. In The Merck Index, 13th Edition, Maryadele JON is cited as author. The book was published in 2001 by Merck Research Lab and was numbered 989(5538): 854(4802).

3. Tripathi KD: Jaypee Brothers Medical Publishers Ltd, New Delhi, 2010: Essentials of Medical Pharmacology, 6th Edition, 485–540.

The work of Khan MR, Shaikh A, and Thaker AK on the creation of a technique for the simultaneous determination and detection of

The solid dosage forms of the medications losartan potassium and hydrochlorothiazide were analyzed

using RP-HPLC. The article is published in the 2012 edition of the International Journal of Pharmaceutical Sciences and Research and is numbered 2(1) and pages 42–45.

5. The study by Gaurav, Sanjay, Dhamesh, and Rajendra M. on the simultaneous estimate of amlodipine besylate and hydrochlorothiazide in combination dose forms was published in the journal Pharmaceuticals. This article is from the 2010 edition of the Stamford Journal of Pharmaceutical Sciences, volume 3, issue 1, pages 49–53.

6. Dipali DW, Pradip D, and Dipali SJ: RP-HPLC Evaluation of a Lisinopril and Hydrochlorothiazide Combination Dosage Form Publication: 2012, International Journal of Pharmaceutical Technology Research, 4: 1570–1574.

The RP-HPLC method was developed by Raja, Himasri, and Ramadevi to estimate the pharmaceutical dosage forms of irbesartan and hydrochlorthiazide simultaneously. Publication date: 2012; volume 2, pages 29–38, International Research Journal of Pharmaceutical and Applied Sciences.

Using the RP-HPLC technique, Lakshamana RA and Bhaskara RV analyzed the tablets of valsartan and hydrochlorthiazide simultaneously. Page 170-174 of the 2011 edition of the International Journal of Pharmaceutical and Industrial Research.

9, Narendra DB, Satyanarayana T, and Ganga RB: RP-HPLC technique for simultaneous measurement of olmesartan and hydrochlorothiazide in mixed pharmaceutical dose form. Vol. 3, Issue 3, of the International Journal of Pharma and Bio Sciences, 2012, pp. 107–115.

RP-HPLC Method for Simultaneous measurement of Telmisartan and Hydrochlorothiazide in tablet dosage form: a study by Wankhede SB, Tajne MR, and Gupta KR. The article was published in 2007 in the Indian Journal of Pharmaceutical Sciences and can be found on pages 298–300.

11. For the measurement of candesartan in both pure and pharmaceutical formulations, Manju LYB and Gowri SD developed a stability-indicating RP-HPLC method. International Journal of Pharmaceutical and

Industrial Research, 2011; 1: 344-349.

12. "Estimation of candesartan cilexetil in bulk and tablet dosage form by UV Spectrophotometric method" by Basawaraj P, Raghavendra R, Suvarna J, Upendra K, and Mahesh GM. Journal of Research in Ayurveda and Pharmacy, International, 2011, 2, 204–206.

Candesartan cilexetil in tablet form determined by spectrofluorimetry; authors: Amir AS and Hanan F. 13. Review and Research in Pharmaceutical Sciences: An International Journal, 2010; 4: 60-63.

A sensitive and easy LC-UV technique for the simultaneous measurement of hydrochlorothiazide and candesartan cilexetil in pharmaceutical formulations was developed by Qutab SS, Razzaq SN, Ashfaq M, Shuja ZA, and Khan IU. Citation: Acta Chromatographica 2007; 19: 119-129.

15. Mathrusri AM, Narendra A, and Ravi KK: LCM technique for concurrent quantitative